Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price decrease of -37.71%. However, over the past six months, we’ve seen a stronger performance of -49.07%. The price of MREO fallen by 9.00% over the last 30 days. And in the last five days, it has fallen by -9.92%.
Mereo Biopharma Group Plc ADR’s market performance has been unstable in recent times.
52-week price history of MREO Stock
Examining the 52-week high and low prices can provide valuable insights into a stock’s current status and future performance. Mereo Biopharma Group Plc ADR’s current trading price is -56.57% away from its 52-week high, while its distance from the 52-week low is 38.41%. The stock’s price range during this time has been between $1.58 and $5.02. The trading volume for the Healthcare sector company’s shares reached about 0.91 million for the day, which was lower than the average daily volume of 1.54 million over the last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Mereo Biopharma Group Plc ADR (MREO) has experienced a quarterly decline of -24.31% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 346.62M and boasts a workforce of 36 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.71, with a change in price of -1.13. Similarly, Mereo Biopharma Group Plc ADR recorded 1,354,735 in trading volume during the last 100 days, posting a change of -34.14%.
MREO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for MREO stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.00.
MREO Stock Stochastic Average
Today, Mereo Biopharma Group Plc ADR’s raw stochastic average for the past 50 days stands at 51.28%, indicating a rise from the raw stochastic average of the last 20 days, which was 18.57%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 37.86% and 52.06% respectively.
